Datum Biotech

Datum Biotech is an Israeli biotechnology company specializing in regenerative medicine through its proprietary GLYMATRIX technology. This platform uses sugar cross-linking to create bio-programmable collagen matrices that mimic the body's natural processes for tissue and bone regeneration. The company's primary commercial portfolio, marketed through its subsidiary Datum Dental, includes the OSSIX line of products such as OSSIX Plus, OSSIX Volumax, and OSSIX Bone, which are used globally in dental guided bone and tissue regeneration procedures. In 2021, Datum Biotech and Datum Dental were acquired by Dentsply Sirona for over $100 million. Additionally, the company founded Datum Orthobiologics in 2018 to adapt its collagen technology for orthopedic applications, including spine fusion and fracture repair.